LivaNova (LIVN) Revenue & Revenue Breakdown
LivaNova Revenue Highlights
Latest Revenue (Y)
$1.15B
Latest Revenue (Q)
$318.60M
Main Segment (Y)
Cardiopulmonary Segment
Main Geography (Y)
UNITED STATES
LivaNova Revenue by Period
LivaNova Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.15B | 12.89% |
| 2022-12-31 | $1.02B | -1.31% |
| 2021-12-31 | $1.04B | 10.83% |
| 2020-12-31 | $934.20M | -13.84% |
| 2019-12-31 | $1.08B | -2.06% |
| 2018-12-31 | $1.11B | 9.35% |
| 2017-12-31 | $1.01B | -16.61% |
| 2016-12-31 | $1.21B | 316.35% |
| 2015-04-30 | $291.56M | 3.38% |
| 2014-04-30 | $282.01M | 10.89% |
| 2013-04-30 | $254.32M | 16.39% |
| 2012-04-30 | $218.50M | 14.72% |
| 2011-04-30 | $190.46M | 13.52% |
| 2010-04-30 | $167.78M | 16.83% |
| 2009-04-30 | $143.60M | 18.45% |
| 2008-04-30 | $121.23M | -7.44% |
| 2007-04-30 | $130.97M | 6.10% |
| 2006-04-30 | $123.44M | 19.33% |
| 2005-04-30 | $103.44M | -6.57% |
| 2004-04-30 | $110.72M | 5.99% |
| 2003-04-30 | $104.47M | 49.00% |
| 2002-04-30 | $70.11M | 46.40% |
| 2000-06-30 | $47.89M | 60.16% |
| 1999-06-30 | $29.90M | 100.67% |
| 1998-06-30 | $14.90M | 964.29% |
| 1997-06-30 | $1.40M | - |
| 1996-06-30 | $1.40M | 40.00% |
| 1995-06-30 | $1.00M | 150.00% |
| 1994-06-30 | $400.00K | 300.00% |
| 1993-06-30 | $100.00K | - |
LivaNova generated $1.15B in revenue during NA 2023, up 12.89% compared to the previous quarter, and up 104.20% compared to the same period a year ago.
LivaNova Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $318.60M | 8.03% |
| 2024-03-31 | $294.91M | -4.90% |
| 2023-12-31 | $310.10M | 8.39% |
| 2023-09-30 | $286.10M | -2.65% |
| 2023-06-30 | $293.90M | 11.58% |
| 2023-03-31 | $263.40M | -4.18% |
| 2022-12-31 | $274.90M | 8.83% |
| 2022-09-30 | $252.60M | -0.63% |
| 2022-06-30 | $254.20M | 5.84% |
| 2022-03-31 | $240.18M | -11.08% |
| 2021-12-31 | $270.10M | 6.67% |
| 2021-09-30 | $253.22M | -4.26% |
| 2021-06-30 | $264.48M | 6.82% |
| 2021-03-31 | $247.60M | -8.16% |
| 2020-12-31 | $269.60M | 12.29% |
| 2020-09-30 | $240.08M | 31.76% |
| 2020-06-30 | $182.21M | -24.83% |
| 2020-03-31 | $242.40M | -15.72% |
| 2019-12-31 | $287.60M | 7.07% |
| 2019-09-30 | $268.61M | -3.09% |
| 2019-06-30 | $277.17M | 10.51% |
| 2019-03-31 | $250.80M | -15.56% |
| 2018-12-31 | $297.00M | 9.16% |
| 2018-09-30 | $272.08M | -5.36% |
| 2018-06-30 | $287.50M | 14.82% |
| 2018-03-31 | $250.40M | -10.06% |
| 2017-12-31 | $278.40M | -10.10% |
| 2017-09-30 | $309.66M | -3.65% |
| 2017-06-30 | $321.39M | 12.73% |
| 2017-03-31 | $285.11M | -8.21% |
| 2016-12-31 | $310.60M | 5.19% |
| 2016-09-30 | $295.27M | -8.02% |
| 2016-06-30 | $321.00M | 11.85% |
| 2016-03-31 | $287.00M | 325.05% |
| 2015-10-18 | $67.52M | -16.65% |
| 2015-07-31 | $81.01M | 9.37% |
| 2015-04-30 | $74.07M | 2.78% |
| 2015-01-31 | $72.07M | -1.84% |
| 2014-10-31 | $73.42M | 1.96% |
| 2014-07-31 | $72.00M | -3.80% |
| 2014-04-30 | $74.85M | 9.76% |
| 2014-01-31 | $68.19M | -2.72% |
| 2013-10-31 | $70.10M | 1.78% |
| 2013-07-31 | $68.87M | 0.77% |
| 2013-04-30 | $68.34M | 9.00% |
| 2013-01-31 | $62.70M | -0.41% |
| 2012-10-31 | $62.96M | 4.37% |
| 2012-07-31 | $60.32M | 4.71% |
| 2012-04-30 | $57.61M | 5.63% |
| 2012-01-31 | $54.54M | 1.57% |
| 2011-10-31 | $53.70M | 1.96% |
| 2011-07-31 | $52.66M | 3.01% |
| 2011-04-30 | $51.12M | 8.58% |
| 2011-01-31 | $47.08M | -0.80% |
| 2010-10-31 | $47.46M | 5.94% |
| 2010-07-31 | $44.80M | -6.15% |
| 2010-04-30 | $47.73M | 16.94% |
| 2010-01-31 | $40.82M | 0.25% |
| 2009-10-31 | $40.72M | 5.76% |
| 2009-07-31 | $38.50M | -0.20% |
| 2009-04-30 | $38.58M | 9.41% |
| 2009-01-31 | $35.26M | -2.14% |
| 2008-10-31 | $36.03M | 6.82% |
| 2008-07-31 | $33.73M | -0.47% |
| 2008-04-30 | $33.89M | 7.83% |
| 2007-04-30 | $31.43M | -7.93% |
| 2006-10-31 | $34.14M | 1.21% |
| 2006-07-31 | $33.73M | -6.43% |
| 2006-04-30 | $36.05M | 24.00% |
| 2005-10-31 | $29.07M | 7.59% |
| 2005-07-31 | $27.02M | 1.35% |
| 2005-04-30 | $26.66M | - |
LivaNova generated $318.60M in revenue during Q2 2024, up 8.03% compared to the previous quarter, and up 120.96% compared to the same period a year ago.
LivaNova Revenue Breakdown
LivaNova Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Neuromodulation Segment | $519.71M | $476.99M | $456.17M | $354.44M | $424.55M |
| Cardiopulmonary Segment | $588.98M | $500.31M | $482.98M | - | - |
| Advanced Circulatory Support Segment | $40.32M | $39.30M | $55.46M | - | - |
| Cardiovascular Segment | - | - | - | $577.08M | $656.65M |
LivaNova's latest annual revenue breakdown by segment (product or service), as of Dec 23: Cardiopulmonary Segment (51.26%), Neuromodulation Segment (45.23%), and Advanced Circulatory Support Segment (3.51%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuromodulation Segment | $142.88M | $133.87M | $136.93M | $128.88M | $133.18M | $120.72M | $127.14M | $121.83M | $117.80M | $110.23M | $121.55M | $113.29M | $117.64M | $103.70M | $109.17M | $98.41M | $57.21M | $89.66M | - | - |
| Cardiopulmonary Segment | $173.71M | $155.89M | $161.47M | $144.83M | $150.60M | $132.07M | $136.46M | $120.96M | $125.82M | $117.08M | - | - | - | - | - | - | - | - | - | - |
| Advanced Circulatory Support Segment | - | - | $10.11M | $10.95M | $9.42M | $9.84M | $9.63M | $8.64M | $9.35M | $11.68M | - | - | - | - | - | - | - | - | - | - |
| Cardiovascular Segment | - | - | - | - | - | - | - | - | - | - | - | $138.63M | $145.88M | $143.17M | $159.60M | $140.88M | $124.53M | $25.21M | - | - |
| Cardiac Surgery | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $28.88M | $33.35M |
| Neuromodulation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $112.54M | $104.27M |
LivaNova's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Cardiopulmonary Segment (54.87%), and Neuromodulation Segment (45.13%).
LivaNova Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| UNITED STATES | $635.04M | $571.56M | $571.30M | $468.63M | $546.48M |
| Europe | $214.79M | $178.80M | $201.53M | $193.37M | $223.18M |
| Locations Excluding The United States And Europe | $303.71M | $271.44M | $262.54M | $272.24M | - |
| Rest Of World | - | - | - | - | $314.50M |
LivaNova's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (55.05%), Locations Excluding The United States And Europe (26.33%), and Europe (18.62%).
Quarterly Revenue by Country
| Country | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $179.54M | $160.62M | $173.22M | $161.58M | $159.97M | $140.27M | $153.79M | $143.41M | $138.09M | $136.27M | $149.83M | $40.14M | $2.21M | $2.72M | $138.00M | $3.13M | $2.49M | - | - | - |
| Europe | $51.26M | $54.34M | $62.56M | $48.13M | $54.46M | $49.64M | $46.31M | $40.00M | $47.37M | $45.13M | $48.95M | $32.85M | $6.12M | $8.28M | $54.76M | $7.95M | $5.35M | - | - | - |
| Locations Excluding The United States And Europe | $87.78M | $79.95M | $74.35M | $76.40M | $79.45M | $73.51M | $74.78M | $69.20M | $68.69M | $58.78M | $71.29M | $50.24M | $6.39M | $10.45M | $76.79M | $10.06M | $9.63M | $671.00K | - | - |
| Rest Of World | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $641.00K | $656.00K |
LivaNova's latest quarterly revenue breakdown by geography, as of Jun 24: UNITED STATES (56.36%), Locations Excluding The United States And Europe (27.55%), and Europe (16.09%).
LivaNova Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BRKR | Bruker | $2.96B | $800.70M |
| ITGR | Integer | $1.60B | $753.01M |
| GMED | Globus Medical | $1.57B | $629.69M |
| CNMD | CONMED | $1.24B | $332.10M |
| LIVN | LivaNova | $1.15B | $318.60M |
| IRTC | iRhythm | $492.68M | $148.05M |
| ATEC | Alphatec | $482.26M | $42.98M |
| GKOS | Glaukos | $314.71M | $95.69M |
| FNA | Paragon 28 | $216.39M | $61.02M |
| KIDS | OrthoPediatrics | $148.73M | $52.80M |
| SIBN | SI-BONE | $138.89M | $39.97M |
| LUNG | Pulmonx | $68.67M | $20.78M |
| NPCE | NeuroPace | $65.42M | $18.12M |
| OFIX | Orthofix Medical | $100.00K | $198.62M |
LIVN Revenue FAQ
What is LivaNova’s yearly revenue?
LivaNova's yearly revenue for 2023 was $1.15B, representing an increase of 12.89% compared to 2022. The company's yearly revenue for 2022 was $1.02B, representing a decrease of -1.31% compared to 2021. LIVN's yearly revenue for 2021 was $1.04B, representing an increase of 10.83% compared to 2020.
What is LivaNova’s quarterly revenue?
LivaNova's quarterly revenue for Q2 2024 was $318.6M, a 8.03% increase from the previous quarter (Q1 2024), and a 8.40% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $294.91M, a -4.90% decrease from the previous quarter (Q4 2023), and a 11.96% increase year-over-year (Q1 2023). LIVN's quarterly revenue for Q4 2023 was $310.1M, a 8.39% increase from the previous quarter (Q3 2023), and a 12.80% increase year-over-year (Q4 2022).
What is LivaNova’s revenue growth rate?
LivaNova's revenue growth rate for the last 3 years (2021-2023) was 11.41%, and for the last 5 years (2019-2023) was 6.39%.
What are LivaNova’s revenue streams?
LivaNova's revenue streams in c 23 are Neuromodulation Segment, Cardiopulmonary Segment, and Advanced Circulatory Support Segment. Neuromodulation Segment generated $519.71M in revenue, accounting 45.23% of the company's total revenue, up 8.96% year-over-year. Cardiopulmonary Segment generated $588.98M in revenue, accounting 51.26% of the company's total revenue, up 17.72% year-over-year. Advanced Circulatory Support Segment generated $40.32M in revenue, accounting 3.51% of the company's total revenue, up 2.60% year-over-year.
What is LivaNova’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of LivaNova was Cardiopulmonary Segment. This segment made a revenue of $588.98M, representing 51.26% of the company's total revenue.